309 related articles for article (PubMed ID: 20581238)
1. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
Schmidt N; Gonzalez E; Visekruna A; Kühl AA; Loddenkemper C; Mollenkopf H; Kaufmann SH; Steinhoff U; Joeris T
Gut; 2010 Jul; 59(7):896-906. PubMed ID: 20581238
[TBL] [Abstract][Full Text] [Related]
2. Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis.
Bai A; Yong M; Ma AG; Ma Y; Weiss CR; Guan Q; Bernstein CN; Peng Z
J Pharmacol Exp Ther; 2010 Jun; 333(3):717-25. PubMed ID: 20237071
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Fissolo N; Kraus M; Reich M; Ayturan M; Overkleeft H; Driessen C; Weissert R
Eur J Immunol; 2008 Sep; 38(9):2401-11. PubMed ID: 18792018
[TBL] [Abstract][Full Text] [Related]
4. Regulation of gut inflammation and th17 cell response by interleukin-21.
Fina D; Sarra M; Fantini MC; Rizzo A; Caruso R; Caprioli F; Stolfi C; Cardolini I; Dottori M; Boirivant M; Pallone F; Macdonald TT; Monteleone G
Gastroenterology; 2008 Apr; 134(4):1038-48. PubMed ID: 18395085
[TBL] [Abstract][Full Text] [Related]
5. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome.
Basler M; Dajee M; Moll C; Groettrup M; Kirk CJ
J Immunol; 2010 Jul; 185(1):634-41. PubMed ID: 20525886
[TBL] [Abstract][Full Text] [Related]
6. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation.
Kalim KW; Basler M; Kirk CJ; Groettrup M
J Immunol; 2012 Oct; 189(8):4182-93. PubMed ID: 22984077
[TBL] [Abstract][Full Text] [Related]
7. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis.
Cannarile L; Cuzzocrea S; Santucci L; Agostini M; Mazzon E; Esposito E; Muià C; Coppo M; Di Paola R; Riccardi C
Gastroenterology; 2009 Feb; 136(2):530-41. PubMed ID: 18996377
[TBL] [Abstract][Full Text] [Related]
9. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis.
De Vry CG; Prasad S; Komuves L; Lorenzana C; Parham C; Le T; Adda S; Hoffman J; Kahoud N; Garlapati R; Shyamsundar R; Mai K; Zhang J; Muchamuel T; Dajee M; Schryver B; McEvoy LM; Ehrhardt RO
Gut; 2007 Apr; 56(4):524-33. PubMed ID: 16950831
[TBL] [Abstract][Full Text] [Related]
10. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice.
Sugimoto K; Hanai H; Tozawa K; Aoshi T; Uchijima M; Nagata T; Koide Y
Gastroenterology; 2002 Dec; 123(6):1912-22. PubMed ID: 12454848
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
Huber JM; Tagwerker A; Heininger D; Mayer G; Rosenkranz AR; Eller K
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F451-60. PubMed ID: 19458122
[TBL] [Abstract][Full Text] [Related]
12. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
Wilck N; Fechner M; Dreger H; Hewing B; Arias A; Meiners S; Baumann G; Stangl V; Stangl K; Ludwig A
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1418-26. PubMed ID: 22516063
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of inflammatory bowel disease in a mouse model of depression.
Ghia JE; Blennerhassett P; Deng Y; Verdu EF; Khan WI; Collins SM
Gastroenterology; 2009 Jun; 136(7):2280-2288.e1-4. PubMed ID: 19272381
[TBL] [Abstract][Full Text] [Related]
14. Fos proteins suppress dextran sulfate sodium-induced colitis through inhibition of NF-kappaB.
Takada Y; Ray N; Ikeda E; Kawaguchi T; Kuwahara M; Wagner EF; Matsuo K
J Immunol; 2010 Jan; 184(2):1014-21. PubMed ID: 20018614
[TBL] [Abstract][Full Text] [Related]
15. Attenuation by dietary taurine of dextran sulfate sodium-induced colitis in mice and of THP-1-induced damage to intestinal Caco-2 cell monolayers.
Zhao Z; Satsu H; Fujisawa M; Hori M; Ishimoto Y; Totsuka M; Nambu A; Kakuta S; Ozaki H; Shimizu M
Amino Acids; 2008 Jun; 35(1):217-24. PubMed ID: 17619120
[TBL] [Abstract][Full Text] [Related]
16. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.
Zhao J; de Vera J; Narushima S; Beck EX; Palencia S; Shinkawa P; Kim KA; Liu Y; Levy MD; Berg DJ; Abo A; Funk WD
Gastroenterology; 2007 Apr; 132(4):1331-43. PubMed ID: 17408649
[TBL] [Abstract][Full Text] [Related]
17. Suppression of experimental colitis by intestinal mononuclear phagocytes.
Qualls JE; Kaplan AM; van Rooijen N; Cohen DA
J Leukoc Biol; 2006 Oct; 80(4):802-15. PubMed ID: 16888083
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
[TBL] [Abstract][Full Text] [Related]
19. Oridonin derivative ameliorates experimental colitis by inhibiting activated T-cells and translocation of nuclear factor-kappa B.
Liu QQ; Wang HL; Chen K; Wang SB; Xu Y; Ye Q; Sun YW
J Dig Dis; 2016 Feb; 17(2):104-12. PubMed ID: 26718746
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.
Shteingart S; Rapoport M; Grodzovski I; Sabag O; Lichtenstein M; Eavri R; Lorberboum-Galski H
Gut; 2009 Jun; 58(6):790-8. PubMed ID: 18978179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
